WST — West Pharmaceutical Services, Inc.

Sentiment turned decisively positive after the 2026-07-23 Q2 print: revenue of $872.3M grew 13.8% YoY (12.7% organic), adjusted EPS of $2.37 topped the ~$2.08 consensus, and full-year organic growth guidance was raised to 10-11%, all driven by High-Value Products for biologics and GLP-1 containment. The stock's tape confirms it — +47.0% over six months and +5.3% over three months as of 2026-09-13 — and sell-side targets have been revised up (UBS initiated with Buy/$415 in September 2026, Deutsche Bank $420, BNP Paribas Exane $447), leaving a consensus average near $407 against a $346.23 spot. The bull case is real but crowded: the TTM P/E of 44.0x is already at the five-year average of 43.1x, and the brief itself flags that commentary is starting to ask whether the growth narrative is fully priced.

The revenue series shows a clear inflection, not a steady trend: $747.5M (Q3'23), $732.1M, $695.3M, $702.0M, $746.9M, $748.5M (Q4'24), $698.2M (Q1'25), then $766.2M, $804.3M, $805.0M, $844.9M and $872.3M (Q2'26). YoY growth went from flat/negative through 2024 and roughly +0.4% in Q1'25, to +9.1%, +7.7%, +7.5%, then +21.0% in Q1'26 and +13.8% in Q2'26 — so the acceleration is real and roughly four quarters old, but Q1'26's +21% is flattered by the easy +0.4% Q1'25 comp. Margins are more mixed than the narrative suggests: gross margin is genuinely expanding on HVP mix (37.7% in Q2'26 vs. 35.7% in Q2'25; 35.1% vs. 33.3% in Q1), but operating margin is flat year-over-year (20.5% in Q2'26 vs. 20.6% in Q2'25) because gross-line gains are being absorbed by opex, R&D ($19.7M vs. $19.1M) and transition/cyber costs. EPS is accelerating faster than revenue (Q2'26 diluted EPS $2.15 vs. $1.82, +18%) on below-the-line items. The one genuinely cautionary line is cash: operating cash flow fell roughly 30% YoY in each of the last two quarters ($124.0M vs. $177.1M in Q2; $89.9M vs. $129.4M in Q1), and Q2 free cash flow of $80.8M was down ~21% YoY — earnings are running ahead of cash conversion.

As of 2026-09-13, WST is not cheap in absolute terms but is not stretched versus its own history either. TTM P/E is 43.99x against a five-year average of 43.09x — dead on its own average; P/S is 7.33x versus a five-year average of 8.40x, actually a discount. PEG (TTM) is 2.57, the stock trades at 8.2x book and ~29.8x EV/EBITDA, and forward P/E is ~38.6x on the $8.97 next-FY EPS estimate, i.e. roughly 3.0x a ~12-13% EPS growth rate. On a quality-adjusted basis this is a premium multiple for a mid-teens grower with a 13.6% ROIC — the market is paying for the moat and for HVP mix, not for cheapness. Verdict: fair-to-slightly-rich, which is exactly consistent with the deterministic score's 'Neutral vs. its own history' label.

The key mismatch to watch: the stock has re-rated +47% in six months on the earnings inflection, but management's own raised FY2026 organic guidance of 10-11% implies H2 2026 reported growth of only roughly 4-6% ($3,073.7M FY2025 base, $1,717.2M already booked in H1 at +17.3%, leaves ~$1,665M/$1,700M for H2 against a $1,609.3M H2'25 base). In other words, guidance itself does not promise the acceleration the tape is pricing. If the Q3 print on 2026-10-22 shows HVP growth holding in the low-to-mid teens, the forward multiple grinds down naturally toward the low-30s as FY2027 EPS builds and the current $346.23 looks fine. If H2 decelerates the way the guidance math implies, a 44x trailing multiple has very little cushion, and the stock's high beta (1.135) to discount rates makes the drawdown fast. This is a stock priced for delivery, not for patience — the adverse case is deceleration, not deterioration.

As of 2026-09-13, RSI(14) sat at 51.83 — squarely neutral, with no overbought or oversold signal despite the size of the run. The stock was 0.24% above its 20-day SMA (~$345, derived) and 0.75% below its 50-day SMA (~$349, derived), while sitting 17.24% above a 200-day SMA of roughly $295. The read: a strong, intact long-term uptrend that has spent the past month digesting (one-month return -1.72%) rather than breaking down, wedged between the 20- and 50-day averages after a +47.0% six-month move. There is no overbought urgency here, which is mildly constructive for entry timing, but also no oversold cushion — the nearest meaningful support is the 50-day area around $349/$340, with the 200-day near $295 as the line that would signal real trend damage. The 52-week range is $223.83-$386, so the stock is ~10% below its high.

• Rate sensitivity: at 44x trailing and ~38.6x forward earnings, WST is a long-duration asset — the brief's own observation that surging bond yields periodically pressure healthcare high-multiple names is a live, recurring headwind that has nothing to do with the business.
• GLP-1 and biologics volume secular shift: GLP-1 therapies were roughly 7% of early-2026 revenue and scaling rapidly, and complex biologics require high-purity containment systems that are hard to substitute — this is the single largest volume driver behind the 2026 revenue inflection.
• Regulatory tightening on container closure integrity: increasingly stringent global requirements for drug-container integrity structurally favor qualified, audited incumbent suppliers like West over low-cost generics, reinforcing switching costs and pricing power.
• Pharma cost pressure and destocking cycles: the flat 2024 revenue ($2.89B quarterly average versus $2.93B in 2023) was driven by customer inventory destocking, proving that even a bottleneck supplier is not immune to drugmaker working-capital cycles; IRA/biosimilar pricing pressure could eventually transmit into component pricing.
• Tariffs, FX and supply-chain localization: West manufactures globally and sells globally, so trade policy and currency translation both move reported revenue independently of underlying organic growth.

• Q3 2026 earnings on 2026-10-22 (pre-market): the critical test of whether High-Value Product growth stays in double digits and whether gross margin holds above 37%, plus any further upward revision to the 10-11% FY2026 organic guidance.
• GLP-1 and biologics packaging volume ramp — incremental drug approvals and label expansions that require West containment systems, which flow disproportionately to the higher-margin Proprietary Products segment.
• Execution updates on the West Vantage transition and the AbbVie SmartDose collaboration integration, both cited as part of the current headwind/opportunity mix.
• New CEO Michel Lagarde's strategic agenda (effective June 2026) — first full year in seat; capital allocation priorities, capacity expansion plans and any portfolio optimization are open questions.
• Further sell-side target revisions — consensus is already clustered at $365-$447, so surprises in either direction move the multiple.

• Valuation compression: 44.0x TTM / ~38.6x forward with a PEG of 2.57 leaves almost no room for error; a single soft quarter can take 15-20% off a multiple this rich without anything structurally breaking.
• Implied H2 2026 deceleration: guidance of 10-11% FY organic growth implies only ~4-6% reported growth in H2 against +17.3% in H1 — the market may be pricing acceleration that management is not actually guiding to.
• Cash conversion is deteriorating: operating cash flow fell ~30% YoY in both Q1 and Q2 2026 while net income rose, and the deterministic score's accruals ratio turned positive (0.74% of total assets) — reported profit is running ahead of cash generated.
• Customer and end-market concentration in High-Value Products — a GLP-1 demand air-pocket or a single large customer's inventory correction would hit the fastest-growing, highest-margin piece of the business disproportionately.
• Operational execution risk: the recent cyberattack and the West Vantage business transition are both unresolved drags that management has characterized as minor, but they are running through a period when the guidance bar is high.
• Rate/factor risk: with a beta of 1.135 and a premium multiple, WST is exposed to any renewed rise in long-bond yields or rotation out of high-multiple healthcare.

West Pharmaceutical is a genuinely high-quality business — regulated, high-switching-cost consumable components, ~21% operating margins, gross margin expanding on HVP mix, a net-cash balance sheet ($435.8M cash vs. $291.2M long-term debt, current ratio 2.82) and a real four-quarter revenue inflection that has finally shown up in the numbers. But as of 2026-09-13 the stock already reflects most of that: 44.0x trailing earnings is exactly its five-year average, forward P/E is ~38.6x on ~12-13% growth, and management's own guidance implies H2 2026 growth roughly a third of H1's rate. This is a quality compounder at a fair-to-full price after a 47% six-month run, not a bargain — accumulate on pullbacks toward the high-$200s/$300s rather than chase at $346, and treat the 2026-10-22 Q3 print as the real referendum on the multiple.

Applied 36x to FY2027E adjusted EPS of ~$10.05 (the $8.97 next-FY estimate grown ~12%), a deliberate discount to WST's 43.1x five-year average P/E to account for the H2-2026 growth deceleration implied by guidance and the deteriorating cash conversion; cross-checked at roughly 25x forward EV/EBITDA (~$350) and against a 7.5% WACC / 3% terminal DCF (~$295, heavily penalized by the current capex-heavy, cash-conversion-weak FCF profile), giving a blended fair value of about $362, roughly 4-5% above the 2026-09-13 spot of $346.23.